Citation Impact 2023
Journal Impact Factor: 6.1
5-year Journal Impact Factor: 7.1
Source Normalized Impact per Paper (SNIP): 1.865
SCImago Journal Rank (SJR): 2.578
Speed 2023
Submission to first editorial decision (median days): 14
Submission to acceptance (median days): 129
Usage 2023
Downloads: 2,432,781
Altmetric mentions: 1,561
Articles
Page 101 of 108
-
Citation: Breast Cancer Research 2000 3:66720
-
Enhanced activity of anti-Lewisyhumanised 3S193 when combined with Taxol
Citation: Breast Cancer Research 2000 3:66718 -
Tailored versus high-dose chemotherapy as adjuvant breast cancer treatment
Citation: Breast Cancer Research 2000 3:66717 -
Vaccination of breast cancer patients with MUC1 keyhole limpet hemocyanin conjugate plus QS-21
Citation: Breast Cancer Research 2000 3:66712 -
Amplification at 17q23 in breast cancer
Citation: Breast Cancer Research 2000 2:66705 -
RhoC oncogene and inflammatory breast cancer
Citation: Breast Cancer Research 2000 2:66703 -
Matrix metalloproteinases and angiogenesis
Citation: Breast Cancer Research 2000 2:66702 -
Mammographic screening does not result in a reduction in breast cancer mortality when added to annual clinical breast examinations
Citation: Breast Cancer Research 2000 2:66701 -
A role for PDGF in breast tumor desmoplasia
Citation: Breast Cancer Research 2000 2:66700 -
The composition of mammary gland stroma regulates tumour cell invasion
Citation: Breast Cancer Research 2000 2:66698 -
Temporal prognostic value of ER
Citation: Breast Cancer Research 2000 2:66697 -
Cognition effects of chemotherapy
Citation: Breast Cancer Research 2000 2:66696 -
Bisphosphonates inhibit breast and prostate cancer cell invasion
Citation: Breast Cancer Research 2000 2:66695 -
A randomised trial of buserelin and tamoxifen in metastatic breast cancer
Citation: Breast Cancer Research 2000 2:66694 -
Thalidomide in patients with metastatic breast cancer
Citation: Breast Cancer Research 2000 2:66692 -
Gemcitabine and vinorelbine in advanced breast cancer
Citation: Breast Cancer Research 2000 2:66688 -
Neoadjuvant hormonal therapy with anastrozole
Citation: Breast Cancer Research 2000 2:66687 -
Liposome-delivered angiostatin inhibits breast cancer growth and metastasis
Citation: Breast Cancer Research 2000 2:66686 -
TALL-104 adoptive immunotherapy in breast cancer
Citation: Breast Cancer Research 2000 2:66685 -
Exemestane as third and fourth line hormonal therapy for metastatic breast cancer
Citation: Breast Cancer Research 2000 2:66684 -
A progesterone receptor polymorphism (PROGINS) and breast cancer risk
Citation: Breast Cancer Research 2000 2:66682 -
High dose raloxifene in patients with advanced breast carcinoma
Citation: Breast Cancer Research 2000 2:66680 -
BRCA1 complex contains multiple DNA repair proteins
Citation: Breast Cancer Research 2000 2:66677 -
neu/erbB-2oncogene in mouse mammary tumorigenesis
Citation: Breast Cancer Research 2000 2:66673 -
Id-1, invasion and steroid response
Citation: Breast Cancer Research 2000 2:66672 -
Stromal-epithelial interactions lead to tumour formation in irradiated mice
Citation: Breast Cancer Research 2000 2:66671 -
p27Kip1 and p18INK4cin T-47D cell cycle arrest
Citation: Breast Cancer Research 2000 2:66669 -
hCds1 phosphorylates BRCA1 after DNA damage
Citation: Breast Cancer Research 2000 2:66667 -
RAFTK/Pyk2-mediated signaling in breast cancer cells
Citation: Breast Cancer Research 2000 2:66665 -
Chromosome 1 in breast cancer progression
Citation: Breast Cancer Research 2000 2:66663 -
High dose therapy in metastatic breast cancer
Citation: Breast Cancer Research 2000 2:66662 -
Effects of flavopiridol on apoptosis and c-erbB2 in breast cancer cells
Citation: Breast Cancer Research 2000 2:66661 -
p53, genetic instability and ras overexpression
Citation: Breast Cancer Research 2000 2:66659 -
p53 mutations as predictors for response to neoadjuvant chemotherapy
Citation: Breast Cancer Research 2000 2:66657 -
High-dose chemotherapy in high-risk breast cancer
Citation: Breast Cancer Research 2000 2:66656 -
Aromatase polymorphisms and breast cancer risk
Citation: Breast Cancer Research 2000 2:66655 -
Risk of breast cancer in users of combined oestrogen-progestogen HRT compared with users of oestrogen alone
Citation: Breast Cancer Research 2000 2:66653 -
Assessment of breast screening programme effectiveness
Citation: Breast Cancer Research 2000 2:66649 -
Computer-assisted mammographic imaging
Computer-assisted mammography imaging comprises computer-based analysis of digitized images resulting in prompts aiding mammographic interpretation and computerized stereotactic localization devices which impr...
Citation: Breast Cancer Research 2000 2:392 -
BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite
BRCA1 and BRCA2 breast cancer susceptibility genes encode proteins, the normal cellular functions of which are complex and multiple, and germ-line mutations in individuals predispose both to breast and to ovaria...
Citation: Breast Cancer Research 2000 3:61 -
Breast imaging technology: Current and future technologies for breast cancer imaging
Citation: Breast Cancer Research 2000 3:14 -
The Jackson Laboratory
Citation: Breast Cancer Research 2000 2:0012 -
BRCA1 function in T lymphocytes: a cellular specificity of a different kind
Recent work by Mak et al demonstrates that mice carrying a T-cell-specific disruption of the brca1 gene display markedly impaired T-lymphocyte development and proliferation in the absence of any increased tendenc...
Citation: Breast Cancer Research 2000 3:11 -
Australian Breast Cancer Information, Support and Advocacy
Citation: Breast Cancer Research 2000 2:0010 -
Whither high-dose chemotherapy in breast cancer?
Four trials of high-dose chemotherapy with stem cell support in breast cancer in the adjuvant and metastatic settings have shown no long-term disease-free or overall survival gain. This relative failure of a s...
Citation: Breast Cancer Research 2000 3:8 -
Breast Cancer News
Citation: Breast Cancer Research 2000 2:0008 -
Database of breast cancer biospecimens and familial data
Citation: Breast Cancer Research 2000 2:0006 -
Syk: a new player in the field of breast cancer
Breast tumor development and progression are thought to occur through a complex, multistep process, including oncogene activation (eg HER2/neu) and mutation or loss of tumor suppressor genes (eg p53). Determin...
Citation: Breast Cancer Research 2000 3:5 -
TeleSCAN
Citation: Breast Cancer Research 2000 2:0004 -
Digital Breast Clinic
Citation: Breast Cancer Research 2000 2:0002